文献速递其他结缔组织病

血管扩张剂与系统性硬化症心脏相关结局:一项探索性分析

Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis.
PubMed 文献 · RMD Open · 2024-12-09

基于法国系统性硬化症国家数据库的多中心前瞻性研究,纳入1048例有治疗数据的患者,采用纵向靶向最小损失估计因果方法分析西地那非、波生坦、ACE抑制剂和伊洛前列素对舒张功能障碍、射血分数降低<50%及肺动脉高压的平均治疗效应。西地那非对3年舒张功能障碍(ATE -2.83%,95%CI -4.06至-1.60,p<0.00001)和射血分数降低<50%(ATE -0.88%,95%CI -1.70至-0.05,p=0.037)有显著效应,对PAH无显著效应;波生坦、ACE抑制剂和伊洛前列素均无显著效应。

要点

  • 西地那非对3年舒张功能障碍的ATE为-2.83%(95%CI -4.06至-1.60,p<0.00001)。
  • 西地那非对射血分数降低<50%的ATE为-0.88%(95%CI -1.70至-0.05,p=0.037)。
  • 波生坦、ACE抑制剂和伊洛前列素对舒张功能障碍、射血分数降低<50%或PAH均无显著效应。

核心结论

  • 采用因果方法,本研究首次且规模最大地提示西地那非可能对系统性硬化症患者的舒张功能障碍和射血分数降低的发生有益。
  • 仍需进一步研究评估血管扩张剂对系统性硬化症患者心脏相关结局的效应,以确认这些探索性结果。

研究设计与样本

  • 研究使用法国系统性硬化症国家数据库的多中心前瞻性研究数据。
  • 采用纵向靶向最小损失估计因果方法,校正混杂和信息性删失。
  • 纳入1048例有治疗相关数据的患者。

主要发现

  • 西地那非对3年舒张功能障碍的平均治疗效应为-2.83%(95%CI -4.06至-1.60,p<0.00001)。
  • 西地那非对射血分数降低<50%的平均治疗效应为-0.88%(95%CI -1.70至-0.05,p=0.037)。
  • 西地那非对肺动脉高压未发现显著效应。
  • 波生坦、ACE抑制剂和伊洛前列素对舒张功能障碍、射血分数降低<50%或肺动脉高压均未显示显著效应。

局限性

  • 原文结论指出仍需进一步研究评估血管扩张剂对系统性硬化症患者心脏相关结局的效应,以确认这些探索性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments. METHODS: We used data from a national multicentric prospective study using the French SSc national database. We estimated the average treatment effect (ATE) of sildenafil, bosentan, angiotensin-converting enzyme (ACE) inhibitors and iloprost on diastolic dysfunction, altered ejection fraction <50% and pulmonary arterial hypertension (PAH) using a causal method, namely the longitudinal targeted minimum loss-based estimation, to adjust for confounding and informative censoring. RESULTS: We included 1048 patients with available data regarding treatment. Regarding sildenafil analyses, the ATE on diastolic dysfunction at 3 years was -2.83% (95% CI -4.06; -1.60, p<0.00001), and the estimated ATE on altered ejection fraction <50% was -0.88% (95% CI -1.70; -0.05, p=0.037). We did not find a significative effect on PAH. Regarding bosentan, ACE inhibitors and iloprost, none of them neither showed a significant effect on diastolic dysfunction, altered ejection fraction <50% or PAH. CONCLUSIONS: Using causal methods, our study is the first and largest suggesting that sildenafil might have benefits among SSc patients regarding diastolic dysfunction and altered ejection fraction occurrence. However, further studies assessing the effect of vasodilators on heart-related outcome among SSc patients are needed to confirm those exploratory results.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Guédon AF, Carrat F, Mouthon L, et al. Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis. RMD Open. 2024. PMID: 39658051. doi:10.1136/rmdopen-2024-004918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。